GlobeNewsWire
25 Sept 2026, 05:00 UTC · 2h ago
Verdict
Headline takes no side. We score ADXN +0.60 across three claims — strongly bullish.
+0.60strongly bullish
More positive than 75% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish · 3 new · 0 priced in
Addex Therapeutics has regained full global rights to its GABAB positive allosteric modulator (PAM) assets previously held under a collaboration with Indivior.
Newannounced today, September 25, 2026
So whatOwnership of the substance use disorder candidate (which completed IND enabling studies) allows for potential licensing revenue or a new partner deal in the next 12 months.
More positive than 93% of claims this week
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
Addex now controls two primary GABAB PAM programs: one for substance use disorders and a second for chronic cough.
Newannounced today, September 25, 2026
So whatMoving the chronic cough program into IND enabling studies will increase the company's quarterly R&D spend starting in the second half of 2026.
More positive than 78% of claims this week
The return of assets follows the planned merger of Indivior's parent company with Supernus Pharmaceuticals, Inc.
Newannounced today, September 25, 2026
More positive than 64% of claims this week
Which stocks this story touches
More positive than 75% of ticker scores this week
The company regained full global rights to a valuable GABAB PAM asset portfolio, providing more strategic flexibility and ownership.
More negative than 69% of ticker scores this week
The company is rationalizing its R&D activities and relinquishing rights to its GABAB PAM assets.
More positive than 54% of ticker scores this week
The company is mentioned as part of a planned merger with Indivior's parent company.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
8h ago
More positive than 34% of relationship scores this week
[mutual] The companies had a research collaboration for GABAB positive allosteric modulator assets, which has now been terminated.
—
ADXN hasn't traded since this ran. Last close $3.46 (Sep 24); the reaction starts at the next open.
ADXN chart →
